Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population With Advanced Lung Cancer at ESMO 2016